

ASX ANNOUNCEMENT

ADMEDUS EXPANDS CARDIOCEL® MARKET AND ANTICIPATES RECORD SALES QUARTER

- CardioCel® enters Hong Kong market and achieves initial sales in Italy and France
- Regenerative tissue product on track for strongest sales quarter

Brisbane, Australia, March 12th, 2015

Admedus Limited (ASX: AHZ) today announced that CardioCel® has entered the market in Hong Kong.

The Company has already received initial orders for CardioCel®, a bio-scaffold used to repair congenital heart deformities and complex heart defects including repairing heart valves.

Entry into Hong Kong continues the expansion of CardioCel® into Asian markets, as part of Admedus' global product launch strategy.

"The initial sales in Hong Kong are important as these countries represent significant cardiovascular markets in the Asian region," said Admedus CEO Mr Lee Rodne. "Expansion in this region is part of our global strategy for CardioCel®."

Admedus also announced that sales for CardioCel® continue to grow, with new initial centres in France and Italy being added to the existing European centres already using the product.

In addition to today's news of continued expansion into the Asian market, Admedus announced that it is on track for the strongest quarter of CardioCel® sales, building on the foundation of key, global centre use that has been established over the past year.

"The sales of CardioCel® continue to grow," added Mr Rodne. "We continue to focus on building the market for CardioCel®. The advantage of the tissue over other options available to surgeons and cardiologists gives patients clear benefits and we are seeing this manifest into product use."

CardioCel® use continues to expand, with 28 European centres and a further 28 centres in the US using the product, with the product now used in over 60 centers globally. Over 1200 patients have benefited from CardioCel® as part of their cardiovascular repair surgery.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 3 9620 5454

Media:

Haley Price

+61 (0) 423 139 163

hprice@admedus.com

Media Europe & Asia

Consilium Strategic Communications

Jessica Hodgson / Ivar Milligan

+44 (0)20 3709 5700

admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group, led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About CardioCel®

CardioCel® is a type of cardiovascular scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair paediatric and adult heart deformities. These deformities range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

CardioCel® is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.